Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Family Medicine
Clinical Trials: Adenocarcinoma
A listing of clinical trials currently looking for volunteers to enroll in Adenocarcinoma studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Birmingham Hematology and Oncology Associates, LLC
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Birmingham : Birmingham Hematology and Oncology Associates, LLC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Birmingham :
Study of Ruxolitinib in Pancreatic Cancer Patients
Mobile : University of South Alabama Mitchell Cancer Institute
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Arizona
Chandler : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Gilbert : Banner Healthcare
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Glendale : Arizona Center for Cancer Care
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Mesa : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Scottsdale : TGen Clinical Research Service at Scottsdale Healthcare
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
View More »
Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Scottsdale : Scottsdale Healthcare
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Scottsdale : Research Site
AMG 172 First in Human Study in Patients With Kidney Cancer
Scottsdale :
AMG 172 First in Human Study in Patients With Kidney Cancer
Scottsdale : Scottsdale Healthcare
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Arkansas
Hot Springs :
Study of Ruxolitinib in Pancreatic Cancer Patients
California
Alhambra : Central Hematology Oncology Medical Group, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Alhambra : Central Hematology Oncology Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Anaheim : Pacific Cancer Medical Center, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Bakersfield : Comprehensive Blood and Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Bakersfield : Comprehensive Blood and Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
View More »
Beverly Hills : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Burbank :
Study of Ruxolitinib in Pancreatic Cancer Patients
Corona : Wilshire Oncology Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Duarte : City of Hope Cancer Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Fountain Valley : Compassionate Cancer Care Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Fresno : California Cancer Associates for Research and Excellence (CCARE)
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Fullerton : Saint Jude Heritage Healthcare
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Glendale : White Memorial Medical Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
La Jolla : UCSD Moores Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Long Beach : Pacific Shores Medical Group
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Long Beach : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Long Beach : Pacific Shores Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Los Angeles : UCLA Community Oncology Practice
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Los Angeles : Comprehensive Hematology Oncology Centers, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Los Angeles : UCLA Community Oncology Practice
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Los Angeles : Samuel Oschin Comprehensive Cancer Institute
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Los Angeles :
Study of Ruxolitinib in Pancreatic Cancer Patients
Oakland : Hematology Oncology Associates
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Oceanside : North County Oncology Medical Clinical Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Orange : Hematology Oncology Medical Group of Orange County, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Orange : Hematology Oncology Medical Group of Orange County
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Palm Springs : Desert Comprehensive Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Palo Alto : Stanford University Medical Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Palo Alto : Stanford University Medical Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Pomona : Wilshire Oncology Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Rancho Cucamonga : Wilshire Oncology Medical Group, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Rancho Mirage : Desert Hematology Oncology Medical Group, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Redondo Beach : Cancer Care Associates Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Redondo Beach : Pacific Shores Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Sacramento : University of California Davis Cancer Center
Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
San Diego : Sharp Health Care
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
San Diego : Sharp Health Care
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
San Francisco : California Pacific Medical Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
San Francisco : UCSF Helen Diller Family Comprehensive Cancer Center
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
San Jose : San Jose Medical Group
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
San Jose : San Jose Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Santa Maria : Central Coast Medical Oncology Corp
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Santa Monica : Sarcoma Oncology Center
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Santa Monica :
Study of Ruxolitinib in Pancreatic Cancer Patients
Stanford : Stanford Cancer Center - Stanford University
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Colorado
Aurora : University of Colorado Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Aurora : University of Colorado at Denver and Health Science Center
Trial of Preoperative Capecitabine Oxaliplatin Cetuximab & Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma
Denver : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Denver : Kaiser Permanente Colorado Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Denver :
Study of Ruxolitinib in Pancreatic Cancer Patients
View More »
Grand Junction : Saint Mary's Regional Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Grand Junction : Saint Mary's Regional Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Connecticut
New Haven : Yale Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Stamford : Hematology Oncology Associates, PC
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Stamford : Hematology Oncology Associates, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Stamford : The Stamford Hospital
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Stamford :
Study of Ruxolitinib in Pancreatic Cancer Patients
Delaware
Newark : Christiana Care Health Services Helen Graham Cancer Center
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
District of Columbia
Washington : Research Site
A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
Washington : Georgetown University
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Florida
Boynton Beach :
Study of Ruxolitinib in Pancreatic Cancer Patients
Ft. Myers :
Study of Ruxolitinib in Pancreatic Cancer Patients
Gainesville : Florida Cancer Specialists
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Jacksonville : Mayo Clinic Jacksonville
Pancreatic Juice Diagnosis From Duodenum
Miami Beach : Mount Sinai Comprehensive Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
View More »
Orlando : Florida Hospital Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Pembroke Pines : Memorial Cancer Institute
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
St. Petersburg : Florida Cancer Specialists
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
St. Petersburg :
Study of Ruxolitinib in Pancreatic Cancer Patients
Tampa : Florida Cancer Specialists
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer
Georgia
Savannah : Memorial University Medical Center
RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
View More »
Atlanta : Georgia Cancer Specialists, P.C.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Atlanta : Peachtree Hematology Oncology Consultants, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Atlanta : Emory University
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Atlanta : Piedmont Hospital Research Institute
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Augusta : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Lawrenceville : Suburban Hematology Oncology Associates, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Hawaii
Honolulu : University of Hawaii Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Illinois
Arllington Heights :
Study of Ruxolitinib in Pancreatic Cancer Patients
Chicago : University of Chicago Comprehensive Cancer Center
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
Chicago : Northwestern University
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Chicago : Northwestern University
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Chicago : The University of Chicago Medical Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
View More »
Chicago : University of Chicago Comprehensive Cancer Center
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Elks Grove Village :
Study of Ruxolitinib in Pancreatic Cancer Patients
Highland Park : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Zion : Cancer Treatment Centers of America (CTCA-Midwestern)
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
Indiana
Goshen : Goshen Center for Cancer Care
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Indianapolis : Indiana University Simon Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Indianapolis :
Study of Ruxolitinib in Pancreatic Cancer Patients
Terre Haute : Providence Medical Group
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Iowa
Sioux City :
Study of Ruxolitinib in Pancreatic Cancer Patients
Kansas
Westwood : University of Kansas Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Kentucky
Crestview Hills : Oncology Hematology Care, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Lexington :
Study of Ruxolitinib in Pancreatic Cancer Patients
Louisville : James Graham Brown Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Louisville : Owsley Brown Frazier Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Louisville :
Study of Ruxolitinib in Pancreatic Cancer Patients
Maryland
Annapolis : Anne Arundel Medical Center, Annapolis Oncology Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Annapolis : Anne Arundel Medical Center, Annapolis Oncology Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gemcitabine in Combination With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Massachusetts
Boston : Dana-Farber Cancer Institute
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
Boston : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Boston : Massachusetts General Hospital Dept. of Mass General Hospital
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Boston : Dana Farber Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Rockland : Please Contact U.S. Medical Information Located in
Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
View More »
Worcester : UMASS Medical School Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Worcester :
Study of Ruxolitinib in Pancreatic Cancer Patients
Michigan
Ann Arbor :
Study of Ruxolitinib in Pancreatic Cancer Patients
Detroit : Wayne State University/Karmanos Cancer Institute Wayne St
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Detroit : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Detroit : Karmanos Cancer Institute Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Detroit :
Study of Ruxolitinib in Pancreatic Cancer Patients
View More »
Grand Rapids : St. Mary's Trinity Healthcare
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Grand Rapids :
Study of Ruxolitinib in Pancreatic Cancer Patients
Kalamazoo : West Michigan Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Kalamazoo : West Michigan Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Novi :
Study of Ruxolitinib in Pancreatic Cancer Patients
Southfield : Providence Cancer Center Oncology and Hematology Care Clinic-Eastside Portland
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Minnesota
Minneapolis : Virginia Piper Cancer Institute
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Minneapolis : Virginia Piper Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Minneapolis :
Study of Ruxolitinib in Pancreatic Cancer Patients
Rochester : Mayo Clinic
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Mississippi
Tupelo : Hematology and Oncology Associates at BridgePoint
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Tupelo : Hematology and Oncology Associates at BridgePoint
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Missouri
Columbia : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Saint Joseph : Saint Joseph Oncology, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Saint Joseph : Saint Joseph Oncology, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Saint Louis : Washington University School of Medicine
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
St Louis : Research Site
AMG 172 First in Human Study in Patients With Kidney Cancer
View More »
St. Louis :
Study of Ruxolitinib in Pancreatic Cancer Patients
Montana
Billings : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Billings : Billings Clinic Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Missoula : Montana Cancer Institute Foundation c/o Montana Cancer Specialists
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Nebraska
Lincoln : Southeast Nebraska Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Omaha : Nebraska Cancer Specialists, Methodist Estabrook Cancer Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Nevada
Henderson : Comprehensive Cancer Centers of Nevada
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Henderson : Comprehensive Cancer Centers of Nevada
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Las Vegas : Comprehensive Cancer Centers of Nevada
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
New Jersey
Basking Ridge : Memoral Sloan Kettering Cancer Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Voorhees :
Study of Ruxolitinib in Pancreatic Cancer Patients
New Mexico
Albuquerque : New Mexico Cancer Care Alliance
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Albuquerque :
Study of Ruxolitinib in Pancreatic Cancer Patients
New York
Bronx : Einstein-Montefiore Institute for Clinical & Translational Research
A Phase 2 Study of REOLYSIN in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
View More »
Buffalo : Roswell Park Cancer Institute
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
Buffalo : Roswell Park Cancer Institute Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Jamaica : Queens Cancer Center of Queens Hospital
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Lake Success :
Study of Ruxolitinib in Pancreatic Cancer Patients
New Hyde Park : Long Island Jewish Medical Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
New York : Beth Israel Comprehensive Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
New York : Saint Luke's-Roosevelt Hospital Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
New York : Memorial Sloan Kettering Cancer Center
Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
New York : Memorial Sloan Kettering Cancer Center MSKCC - SC
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
New York : Beth Israel Comprehensive Cancer Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
New York : New York University Langone Medical Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
New York : Memorial Sloan-Kettering Cancer Center 1275 York Avenue
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
New York : Weill Medical College of Cornell University
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Rochester : University of Rochester, James P. Wilmot Cancer Center
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
Rochester : University of Rochester Medical Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Sleepy Hollow : Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Syracuse : Research Foundation of State University of New York
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
North Carolina
Chapel Hill : University of North Carolina Lineberger Comprehensive Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Chapel Hill : UNC - Chapel Hill
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Durham : Duke University Medical Center, Comprehensive Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Durham : Research Site
A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
Durham : Duke University Medical Center
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
View More »
Durham :
Study of Ruxolitinib in Pancreatic Cancer Patients
Greensboro : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Greensboro : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Greensboro : Cone Health Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Hendersonville : Hendersonville Hematology and Oncology at Pardee Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Hickory :
Study of Ruxolitinib in Pancreatic Cancer Patients
High Point : Emerywood Hematology and Oncology
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
High Point : Emerywood Hematology and Oncology
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Raleigh : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Raleigh : Rex Cancer Center UNC Healthcare Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Winston Salem : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Winston Salem : University of Wake Forest Baptist Medical Center
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
North Dakota
Bismarck : St. Alexis Medical Center-Mid Dakota Clinic PC Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Ohio
Blue Ash : Oncology Hematology Care, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Canton :
Study of Ruxolitinib in Pancreatic Cancer Patients
Cincinatti : Oncology Hematology Care, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Cincinnati : University of Cincinnati Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Columbus : The Ohio State University Comprehensive Cancer Center
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
View More »
Columbus : Ohio State University
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
Dayton :
Study of Ruxolitinib in Pancreatic Cancer Patients
Middletown : Signal Point Clinical Research Center, LLC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Wilmington : Oncology Hematology Care, Inc.
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Oklahoma
Tulsa :
Study of Ruxolitinib in Pancreatic Cancer Patients
Tulsa : Cancer Treatment Centers of America (CTCA-Southwestern)
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
Oregon
Bend :
Study of Ruxolitinib in Pancreatic Cancer Patients
Portland : Kaiser Permanente Northwest Region Oncology Hematology
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Portland : Kaiser Permanente NW Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Portland :
Study of Ruxolitinib in Pancreatic Cancer Patients
Pennsylvania
Abington : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Camp Hill : PinnacleHealth
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Daville :
Study of Ruxolitinib in Pancreatic Cancer Patients
Harrisburg : PinnacleHealth
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Harrisburg : Pinnacle Health
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
View More »
Philadelphia : Kimmel Cancer Center at Jefferson University
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Philadelphia : Research Site
A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
Philadelphia : Thomas Jefferson University
Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Philadelphia : Fox Chase Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Philadelphia : Cancer Treatment Centers of America (ERMC)
Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer
Pittsburgh : Hillman Cancer Center
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Pittsburgh : University of Pittsburgh Cancer Institute
Phase II Study of Irinotecan and Panitumumab
Pittsburgh : University of Pittsburgh Cancer Institute
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Pittsburgh :
Study of Ruxolitinib in Pancreatic Cancer Patients
Willow Grove : Abington Hematology Oncology Associates, Inc.
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
South Carolina
Charleston : Charleston Hematology Oncology Associates, PA
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Charleston : Charleston Hematology Oncology Associates
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Charleston : Medical University of South Carolina
Feasibility and Safety Study in Patients With Metastatic Pancreatic Adenocarcinoma
Charleston : Medical University of South Carolina - Hollings Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Columbia : South Carolina Oncology Associates
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
View More »
Columbia : South Carolina Oncology Associates
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Florence : McLeod Regional Medical Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Greenville : Gynecologic Oncology Research & Development, LLC
A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation
Greenville : Institute of Translational Oncology Research
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Tennessee
Knoxville : Tennessee Cancer Specialists
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Knoxville : Center for Biomedical Research
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Knoxville :
Study of Ruxolitinib in Pancreatic Cancer Patients
Nashville : Sarah Cannon Research Institute
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Nashville : Tennessee Oncology, PLLC
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
View More »
Nashville : Tennessee Oncology, PLLC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Nashville : Vanderbilt-Ingram Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Nashville : Tennessee Oncology, PLLC
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
Texas
Abilene : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Bedford : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Corpus Christi : Coastal Bend Cancer Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Dallas : Texas Oncology - Baylor Sammons Cancer Center
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
Dallas : Mary Crowley Cancer Research Centers - Medical City
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
View More »
Dallas : University of Texas Southwestern Medical Center at Dallas
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Dallas : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Dallas : Mary Crowley Cancer Center
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
Fort Worth : Center for Cancer and Blood Disorders, PC
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Fort Worth : Center for Cancer and Blood Disorders, PC
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Garland : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Houston : MD Anderson Cancer Center/University of Texas MD Anderson 2
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Houston : UT MD Anderson Cancer Center
Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas
Houston : UT MD Anderson Cancer Center
Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
Houston : UT MD Anderson Cancer Center
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
Houston : UT MD Anderson Cancer Center
Prostate Conformal Cryotherapy
Lubbock : Joe Arrington Cancer Research and Treatment Center
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Lubbock : Joe Arrington Cancer Research and Treatment Center
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Plano : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
San Antonio : University of Texas Health Science Center at San Antonio
A Phase 1 Study of MLN8237 in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
San Antonio : Novartis Investigative Site
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
San Antonio : South Texas Oncology and Hematology, PA
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
San Antonio :
Study of Ruxolitinib in Pancreatic Cancer Patients
Tyler : Texas Oncology - Tyler
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
Weatherford : The Center for Cancer and Blood Disorders
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Utah
Murray : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Salt Lake City : Utah Cancer Specialists
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Salt Lake City : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman UT
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
View More »
Salt Lake City : Utah Cancer Specialists
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Virginia
Charlottesville : University of Virginia Health System
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Fairfax : Virginia Cancer Specialists, PC
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Midlothian : Virginia Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Norfolk : VA Oncology Associates
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Norfolk : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
View More »
Richmond : Virginia Cancer Institute
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Richmond : Virginia Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Richmond : Virginia Piper Cancer Institute
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
Richmond :
Study of Ruxolitinib in Pancreatic Cancer Patients
Roanoke : Carilion GYN Oncology Associates
A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation
Winchester : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Woodbridge : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Washington
Seattle : Seattle Cancer Care Alliance / University of Washington
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma
Seattle : Virginia Mason Medical Center
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
Seattle : Virginia Piper Cancer Institute
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Seattle : Seattle Cancer Care Alliance Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Seattle : Swedish Medical Center Cancer Institute
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
View More »
Tacoma : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Wisconsin
Green Bay :
Study of Ruxolitinib in Pancreatic Cancer Patients
Madison : University of Wisconsin Comprehensive Cancer Center
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma
Milwaukee : Medical College of Wisconsin - Division of Neoplastic Diseases and Related Disorders
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Milwaukee : Medical College of Wisconsin
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Argentina
Ciudad Autonoma de Buenos Aires : Instituto de Oncologia Angel H. Roffo
Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application
Australia
Box Hill : 1200.123.6104 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Camperdown : 1200.123.6101 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Chermside : 1200.123.6102 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Heidelberg : 1200.123.6105 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Kogarah : 1200.123.6107 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
View More »
Kurralta Park : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Nedlands : 1200.123.6106 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Austria
Linz : KH Elisabethinen Linz
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
Linz : AKh Linz
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
Salzburg : Universitätsklinik für Innere Medizin III
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
Wels : Klinikum Kreuzschwestern Wels GmbH
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
Zams : St. Vinzenz Krankenhaus Betriebs GmbH
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
Belgium
Brussels : Novartis Investigative Site
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
Brussels (anderlecht) : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Brussels (woluwe-st-lambert) : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Gent : Novartis Investigative Site
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
Jette : AZ VUB
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
View More »
Leuven : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Liege : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Wilrijk : Novartis Investigative Site
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Canada
Brampton : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Edmonton : Cross Cancer Institute
First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.
Edmonton : 1200.123.1005 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Edmonton : Novartis Investigative Site
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Halifax : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
View More »
Laval : Research Site
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Montreal : Jewish General Hospital
Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate
Montreal : Montreal General Hospital
Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate
Montreal : 1200.123.1001 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Montreal : 1200.123.1007 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Oshawa : 1200.123.1006 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Ottawa : 1200.123.1003 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Rimouski : GSK Investigational Site
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Surrey : 1200.123.1004 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Toronto : Novartis Investigative Site
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Toronto : Princess Margaret Hospital
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy
Vancouver : 1200.123.1002 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
China
Beijing : Chinese People's Liberation Army (PLA) General Hospital
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Beijing : 1200.123.8606 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Beijing : 1200.123.8608 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Beijing : Department of GI Oncology, Peking University, School of Oncology
Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
Guangzhou : 1200.123.8601 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
View More »
Nan Ning : 1200.123.8607 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Shanghai : 1200.123.8604 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Shanghai : 1200.123.8605 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Shanghai : 1200.123.8602 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Shenyang : 1200.123.8603 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Czech Republic
Brno : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Olomouc : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Praha 2 : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
France
Bayonne : 1200.123.3307 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Caen Cedex 05 : 1200.123.3305 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Créteil Cedex : 1200.123.3303 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
La Tronche : 1200.123.3309 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Limoges Cedex : 1200.123.3308 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
View More »
Lyon Cedex 08 : 1200.123.3301 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Saint Herblain Cedex : 1200.123.3302 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Saint-Pierre Cedex -La Réunion : 1200.123.3306 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Toulouse Cedex 3 : Novartis Investigative Site
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Villejuif : Research Site
AMG 172 First in Human Study in Patients With Kidney Cancer
Villejuif : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Germany
Berlin : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Bielefeld : Onkologische Schwerpunktpraxis Bielefeld
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen (Plus ZA/IL-2) CLDN18.2-positive Gastric Cancer
Bielefeld : Onkologische Schwerpunktpraxis Bielefeld
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
Brandenburg : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Braunschweig : Prof. Dr. F. Lordick
Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas
View More »
Chemnitz : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Cottbus : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Darmstadt, Germany : Please contact Merck KGaA Communication Center located in
Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer
Dresden : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Elstra : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Essen : Universitätsklinikum Essen, Innere Klinik Tumorforschung
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen (Plus ZA/IL-2) CLDN18.2-positive Gastric Cancer
Essen : 1200.123.4901 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Essen : Novartis Investigative Site
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Esslingen : 1200.123.4905 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Freiburg : University Hospital Freiburg Gynecological Clinic
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Freital : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Fürstenwalde : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Halle/Saale : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Halle/Saale : Universitätsklinikum Halle/Saale; Poliklinik für innere Medizin iV
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen (Plus ZA/IL-2) CLDN18.2-positive Gastric Cancer
Hamburg : 1200.123.4904 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Hamburg : University Hospital Hamburg-Eppendorf
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Hamburg : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Hannover : Novartis Investigative Site
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
Heidelberg : Research Site
AMG 172 First in Human Study in Patients With Kidney Cancer
Kassel : Hospital Kassel
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Köthen : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Kronach : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Leipzig : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Leipzig : Hospital
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Magdeburg : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Mainz : 1200.123.4902 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Mainz : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Mannheim : Tagestherapiezentrum am ITM & III. Medizinische Klinik Universitätsmedizin Mannheim
Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach
Meiningen : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Mühlhausen : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Münster : 1200.123.4903 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Parchim : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Plauen : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Scheibenberg : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Torgau : Clinic
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Werdau : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Würzburg : University Hospital Würzburg
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
Zittau : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Zwickau : Practice
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
Hong Kong
Hongkong : 1200.123.8522 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Shatin : 1200.123.8521 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Hungary
Budapest :
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Budapest : Semmelweis University; Clinic for Pulmonology
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
Debrecen : University of Debrecen Medical and Health Science Center, Clinic of Pulmonology
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
Deszk :
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Deszk : Hospital for Thoracic Diseases of Csongrad County Local Government
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung
View More »
Mátraháza :
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Pecs :
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Szekesfehervar :
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Törökbálint :
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
India
Bangalore : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Chennai : Lifeline Multispeciality Hospitals Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Chennai : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Chennai : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Hyderabad : Basavatarakam Indo-American Cancer Hospital Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
View More »
Hyderabad : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Mumbai : Jaslok Hospital & Research Centre Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Nagpur : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Nashik : Shatabdi Superspeciality Hospital Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Pune : Ruby Hall Clinic Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Pune : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Thiruvananthapuram : Regional Cancer Center Updated
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Vellore : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Ireland
Dubliin 9 : 1200.123.3532 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Dublin 8 : 1200.123.3531 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Israel
Haifa : Rambam medical Center
Immunochemotherapy for Metastatic Renal Cell Carcinoma
Jerusalem : Hadassah Medical Organization
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas
Jerusalem : Shaare Zedek Medical Center
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas
Ramat Gan : Sheba Medical Center
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas
Italy
Ancona : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Milano : Novartis Investigative Site
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Milano : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Pisa : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Roma : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Japan
Chuo-ku : Novartis Investigative Site
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
Fukuoka-shi : Kyushu University
Pancreatic Juice Diagnosis From Duodenum
Kashiwa : Novartis Investigative Site
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
Koto : Novartis Investigative Site
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
Takatsuki : Novartis Investigative Site
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
Korea, Republic of
Anyang : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Cheonju-si : 1200.123.8203 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Daegu : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Goyang-si : National Cancer Center
Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
Incheon : 1200.123.8204 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
View More »
Jeonju : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Jeonnam : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Seongnam : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Seoul : 1200.123.8201 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Seoul : 1200.123.8205 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Seoul : 1200.123.8206 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Seoul : 1200.123.8202 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Seoul : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Songpa-gu : Asan Medical Center
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC)
Latvia
Riga :
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Netherlands
Amsterdam : Nederlands Kanker Instituut/Antonie van Leeuwenhoek Ziekenhuis
Optical Detection of Peripheral Nerve Bundles During Surgery
Rotterdam : Novartis Investigative Site
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Norway
Oslo : 1200.123.4701 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Trondheim : 1200.123.4702 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Poland
Otwock : Novartis Investigative Site
RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
Singapore
Singapore : 1200.123.6502 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Singapore : 1200.123.6501 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Spain
Barcelona : Novartis Investigative Site
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Barcelona : Novartis Investigative Site
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Barcelona : Novartis Investigative Site
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
Barcelona : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Barcelona : ACROSS
XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
View More »
La Coruna : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
La Coruña : Centro Oncológico de Galícia
Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Madrid : Local Institution
An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy
Madrid : 1200.123.3402 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Madrid : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Malaga : 1200.123.3404 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Oviedo : 1200.123.3405 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Oviedo : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Santander : 1200.123.3403 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Sevilla : 1200.123.3401 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Sevilla : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Sweden
Göteborg : 1200.123.4603 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Linköping : 1200.123.4602 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Lund : 1200.123.4601 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Stockholm : Dept. of Clinical Science, Intervention and Technology, Div. of surgery, Karolinska University Hospital, Huddinge
AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer
Stockholm : 1200.123.4604 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Switzerland
St. Gallen : Novartis Investigative Site
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Taiwan
Taichung : 1200.123.8864 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Taichung : 1200.123.8865 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Tainan : 1200.123.8866 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Taipei : 1200.123.8862 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Taipei : 1200.123.8861 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
View More »
Taipei : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Taiwan : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Tao-Yuan : 1200.123.8863 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
United Kingdom
Aberdeen : 1200.123.4401 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Aberdeen : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Birmingham : 1200.123.4406 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Cambridge : Cambridge University Hospitals NHS Foundation Trust
Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)
Cardiff : 1200.123.4402 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
View More »
Edinburgh : 1200.123.4404 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Guildford : 1200.123.4405 Boehringer Ingelheim Investigational Site
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Liverpool : Novartis Investigative Site
Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients
London : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Maidstone : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Manchester : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Sutton : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
Wolverhampton : Research Site
Safety and Efficacy of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients
